Page 154 - pharma 1 theoretical updated MNU_Neat

Clinical pharmacy 2024/2025 Level 3 Pharm D Pharmacology 1 (PO 502)

2- Mipomersen (Kynamro)

 In January 2013, the FDA approved Mipomersen an antisense
Mechanism oligonucleotide inhibitor of apo B, as an orphan drug for the
management of homozygous familial hypercholesterolemia

 indicated as an adjunct therapy to lipid-lowering agents and to
lifestyle changes for reducing LDL-C, apo B, TC, and non–HDL-C
Effect levels.

 treat homozygous familial hypercholesterolemia and is
administered by subcutaneous injection

| P a g e - 138 -